BD FACSAria II for NJMS Flow Cytometry Core

描述（由申请人提供）：此共享仪器补助金（SIG）申请申请资金，用于购买位于新泽西医学院流式细胞术核心实验室的最先进的Becton-Dickinson FACSAria II细胞分选仪。FACSAria II细胞分选仪与已有11年历史、技术过时的FACSAria II细胞分选仪相比，具有许多优势。最重要的是，FACSAria II是一种紧凑的桌面分选机，可以放置在Baker BioPROTect III II类生物安全柜中，这也是本提案所要求的。FACSAria II将配备气溶胶管理选项，以增加操作人员的保护。这些功能对于需要分选活的人类细胞和细胞系或活的病原体感染细胞（包括艾滋病毒感染细胞）的大多数用户来说是必不可少的；这些项目目前无法使用facadvantage进行，因为它缺乏这些安全功能。仪器的其他功能对于我们的SIG研究人员来说是必要的，包括四路分选，四种激光器（355nm (UV), 488nm， 561nm和640nm），能够检测多达14个参数，用于冷冻和冷却分选前和分选后样品的温度控制选项，以及用于将固定数量的细胞沉积到板或载玻片上的自动细胞沉积单元。FACSAria与facadvantage相比具有其他优势，这将使我们所有的用户受益：它更快，更高效，其在BioPROtect III中的外壳将促进无菌分类。该应用程序由10个主要用户和9个次要用户提交的项目支持；激光器和配件的选择是为了满足这一非常多样化的调查人员的分类需求。虽然一些研究人员在传染病免疫学领域工作，包括艾滋病毒免疫学、寄生虫免疫学、先天免疫和细胞因子，但其他研究人员在不同领域工作，如癌细胞生物学、干细胞生物学、辐射生物学、心血管生物学和狼疮。这种研究兴趣的多样性反映在这些SIG研究人员由NIH的六个不同研究所资助：NIAID， NCI， NIGMS， NIDDK， NHBLI和NIMH。所有这些研究者在他们的研究中广泛使用流式细胞术，几乎所有人都有重要的分选经验。对这一FACSAria申请有强有力的机构承诺：医学院已承诺为该仪器的全职操作员和服务合同提供持续资金。这些费用将部分由SIG调查人员和其他调查人员为利用这项强大的技术而招募的用户费用抵消。FACSAria将得到强大的行政结构的支持，包括由流式细胞术核心咨询委员会监督，该委员会由SIG PI Fitzgerald-Bocarsly博士担任主席，他也是流式细胞术和免疫学核心实验室的科学主任。总的来说，将FACSAria II引入我们的大学社区，预计将大大提高我们研究人员的生产力和对生物医学科学的贡献。

DESCRIPTION (provided by applicant): This Shared Instrumentation Grant (SIG) application requests funds for the purchase of a state-of-the-art Becton-Dickinson FACSAria II cell sorter to be located in the Flow Cytometry Core Laboratory at the New Jersey Medical School. The FACSAria II cell sorter has numerous advantages over the 11 year-old, technologically outdated FACSVantage it will replace. Most importantly, the FACSAria II is a compact, desk- top sorter that can be placed in a Baker BioPROTect III class II biological safety cabinet, which is also requested in this proposal. The FACSAria II will be equipped with the aerosol management option for added operator protection. These features are essential to the majority of our users who need to sort either live human cells and cell lines or live, pathogen-infected cells, including HIV-infected cells; these projects cannot currently be carried out using the FACSVantage, which lacks these safety features. Additional features of the instrument that are necessary for our SIG investigators include four-way sorting, four lasers (355 nm (UV), 488 nm, 561nm and 640 nm) with the capability of detecting up to 14 parameters, a temperature control option for refrigeration and cooling of the pre- and post-sort samples, and an automatic cell deposition unit for desposition of fixed numbers of cells into plates or onto slides. The FACSAria has additional advantages over the FACSVantage that will benefit all of our users: it is faster and more efficient and its housing in the BioPROtect III will facilitate aseptic sorts. This application is supported by projects submitted by 10 major users and 9 minor users; the lasers and accessories were chosen to meet the sorting needs of this very diverse group of investigators. While a number of the investigators work in the area of infectious disease immunology, including, e.g., HIV immunology, parasite immunology, innate immunity, and cytokines, other investigators work in diverse areas such as cancer cell biology, stem cell biology, radiation biology, cardiovascular biology and lupus. This diversity in research interests is reflected in the fact that these SIG investigators are funded by six different institutes at the NIH: the NIAID, NCI, NIGMS, NIDDK, NHBLI and NIMH. All of these investigators extensively use flow cytometry in their studies, and nearly all have significant experience with sorting. There is strong institutional commitment to this FACSAria application: the medical school has committed ongoing funds for a full-time operator and service contract for the instrument. These costs will be offset, in part, by users fees from the SIG investigators and other investigators recruited to utilize this powerful technology. The FACSAria will be supported by a strong administrative structure including oversight by the Flow Cytometry Core Advisory Committee, which is chaired by the SIG PI, Dr. Fitzgerald-Bocarsly, who is also the Scientific Director of the Flow Cytometry and Immunology Core Laboratory. Overall, the introduction of this FACSAria II to our university community is expected to greatly enhance our investigators' productivity and contribution to biomedical science.